Skip to main content

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.